Eli Lilly Raises 2013 Guidance After Q2 Sales Rise

July 24 (Bloomberg) -- Eli Lilly & Co., the maker of the antidepressant Cymbalta and diabetes treatment Humalog, raised its full-year guidance after second-quarter sales grew faster than expected and cost-cutting programs took effect. Olivia Sterns reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

Draghi, Yellen and the Expectations of Global Markets
01:08 - Bloomberg's Simon Kennedy and Michael McKee examine expectations for further stimulus from the European Central Bank on Thursday and watching for signals in comments this week from Federal Reserve Chair Janet Yellen about a potential rate hike from the bank. They speak on "Bloomberg Markets." (Source: Bloomberg)
  • The Impact of Geopolitics on Emerging Markets
  • As Heard on 'Bloomberg ‹GO›': 11/30
  • Berg: Exceptional Hedge Fund Managers Take No New Money